TrialInternational journal of clinical oncology2022

Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma.

Koji Kato et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.